How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,766 results for

adhd Methylphenidate

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. (PubMed)

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude (...) of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non-serious adverse events.To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non-randomised studies.In January 2016, we searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, 12 other databases

2018 Cochrane

2. Methylphenidate remains first-choice drug treatment for children and young people with ADHD

Methylphenidate remains first-choice drug treatment for children and young people with ADHD Methylphenidate remains first-choice drug treatment for children and young people with ADHD Discover Portal Discover Portal Methylphenidate remains first-choice drug treatment for children and young people with ADHD Published on 6 November 2018 doi: The stimulant methylphenidate has the best balance of effectiveness against side effects in children and young people with attention deficit hyperactivity (...) guidance say on this issue? NICE updated its guidance on the diagnosis and management of ADHD in March 2018. It recommends methylphenidate (either short or long-acting) as the first line drug treatment for children (aged five years and over) and young people with ADHD. If a six-week trial does not show enough benefit, it recommends switching to once daily lisdexamfetamine. The shorter acting dexamfetamine can be considered for those whose symptoms respond to lisdexamfetamine but who cannot tolerate

2019 NIHR Dissemination Centre

3. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study

Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study The benefits of long-term use of methylphenidate treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed in clinical practice, are unclear. The authors investigated whether methylphenidate remains beneficial after 2 years of use.Ninety-four children and adolescents (ages 8-18 years) who had been (...) treated in regular care with methylphenidate for more than 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg/day of extended-release methylphenidate) or gradual withdrawal over 3 weeks, to 4 weeks of placebo. The primary outcome measure was the investigator-rated ADHD Rating Scale (ADHD-RS); secondary outcome measures were the investigator-rated Clinical Global Impressions improvement scale (CGI-I) and the Conners' Teacher Rating Scale-Revised: Short

2019 EvidenceUpdates

4. Can methylphenidate be used for adults with attention deficit hyperactivity disorder (ADHD)?

Can methylphenidate be used for adults with attention deficit hyperactivity disorder (ADHD)? application/msword

2017 Specialist Pharmacy Services

5. Effects of methylphenidate on the ERP amplitude in youth with ADHD: A double-blind placebo-controlled cross-over EEG study. (PubMed)

Effects of methylphenidate on the ERP amplitude in youth with ADHD: A double-blind placebo-controlled cross-over EEG study. Methylphenidate (MPH) is a first line drug for attention-deficit/hyperactivity disorder (ADHD), yet the neuronal mechanisms underlying the condition and the treatment are still not fully understood. Previous EEG studies on the effect of MPH in ADHD found changes in evoked response potential (ERP) components that were inconsistent between studies. These inconsistencies (...) highlight the need for a well-designed study which includes multiple baseline sessions and controls for possible fatigue, learning effects and between-days variability. To this end, we employ a double-blind placebo-controlled cross-over study and explore the effect of MPH on the ERP response of subjects with ADHD during a Go/No-Go cognitive task. Our ERP analysis revealed significant differences in ADHD subjects between the placebo and MPH conditions in the frontal-parietal region at 250ms-400ms post

Full Text available with Trip Pro

2019 PLoS ONE

6. Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater

Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Article Text Perspective Methylphenidate for ADHD in children and adolescents: throwing the baby out

Full Text available with Trip Pro

2016 Evidence-Based Mental Health

7. Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality?

Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality? Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ Article Text Perspective Evidence on methylphenidate in children and adolescents with ADHD

Full Text available with Trip Pro

2016 Evidence-Based Mental Health

8. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. (PubMed)

Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Symptoms of attention deficit hyperactivity disorder (ADHD), diagnosed mainly in children, often persist into adulthood. Adults in this group have a high rate of other psychiatric problems and functional difficulties in a number of key areas such as academic achievement, interpersonal relationships, and employment. Although the usefulness of immediate-release methylphenidate in children has been (...) authors of recently published trials.We included all randomized trials comparing immediate-release methylphenidate versus placebo in participants aged 18 years or older with ADHD. We excluded trials conducted on subpopulations of adults with ADHD such as adults with both ADHD and substance dependence.Two review authors independently selected trials, extracted data, and assessed trial risk of bias. We contacted authors of trials to ask for additional and missing data. For dichotomous outcomes, we

2014 Cochrane

9. Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial (PubMed)

Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial In some children with ADHD, sub-optimal levels of various nutrients including PUFA especially omega-3 has been observed, and contradictory reports exist on the results of studies conducted on the positive therapeutic effects of PUFA in patients with ADHD.The aim of this study was to investigate the effectiveness of methylphenidate and PUFA on treatment of patients (...) with ADHD in Zahedan, Iran.In this clinical trial, 40 children between 6 and 12 years of age with ADHD were investigated in Zahedan in 2014. Patients were randomly divided into two groups of methylphenidate plus PUFA and methylphenidate plus placebo. ADHD rating scale was filled before and after the study for patients of both groups. Finally, data were analyzed using SPSS18, paired-samples t-test and chi-square.Mean age of patients was 2.9±1.8 years. Thirty-three children (82.5%) were boys and seven

Full Text available with Trip Pro

2017 Electronic physician

10. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study. (PubMed)

Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study. The benefits of long-term use of methylphenidate treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed in clinical practice, are unclear. The authors investigated whether methylphenidate remains beneficial after 2 years of use.Ninety-four children and adolescents (ages 8-18 years) who had been (...) treated in regular care with methylphenidate for more than 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg/day of extended-release methylphenidate) or gradual withdrawal over 3 weeks, to 4 weeks of placebo. The primary outcome measure was the investigator-rated ADHD Rating Scale (ADHD-RS); secondary outcome measures were the investigator-rated Clinical Global Impressions improvement scale (CGI-I) and the Conners' Teacher Rating Scale-Revised: Short

2019 American Journal of Psychiatry

11. Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD. (PubMed)

Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD. Neurofeedback (NF) has gained increasing interest among non-pharmacological treatments for Attention Deficit Hyperactivity Disorder (ADHD). NF training aims to enhance self-regulation of brain activities. The goal of the NEWROFEED study is to assess the efficacy of a new personalized NF training device, using two different protocols according (...) to each child's electroencephalographic pattern, and designed for use at home. This study is a non-inferiority trial comparing NF to methylphenidate.The study is a prospective, multicentre, randomized, reference drug-controlled trial. One hundred seventy-nine children with ADHD, aged 7 to 13 years will be recruited in 13 clinical centres from 5 European countries. Subjects will be randomized to two groups: NF group (Neurofeedback Training Group) and MPH group (Methylphenidate group). Outcome measures

2019 BMC Psychiatry

12. Cost of ADHD treatment using methylphenidate and atomoxetine in the South African private healthcare sector. (PubMed)

Cost of ADHD treatment using methylphenidate and atomoxetine in the South African private healthcare sector. Introduction: The prevalence of Attention-Deficit/Hyperactivity Disorder (ADHD) has risen over the last two decades, with a corresponding increase in the cost of its medication. Drug utilization studies in South Africa focusing on ADHD are limited. Areas covered: The primary aim was to determine the cost of methylphenidate and atomoxetine (used for ADHD). The Intercontinental Marketing (...) Service (IMS) database which contains data of the private healthcare sector was interrogated from 2013 to 2016 (48-month period) focussing on methylphenidate and atomoxetine. Drug consumption was expressed in number of DDDs, DDDs/1000 inhabitants/day and cost in Rands. Expert opinion: Methylphenidate-containing products constituted a considerably higher percentage of the market share when compared to atomoxetine (90.30% versus 9.70%). The DDD/1000 inhabitants/day for methylphenidate was 6.010

2019 Expert review of pharmacoeconomics & outcomes research

13. Effect of sweet almond syrup versus methylphenidate in children with ADHD: A randomized triple-blind clinical trial. (PubMed)

Effect of sweet almond syrup versus methylphenidate in children with ADHD: A randomized triple-blind clinical trial. Attention-deficit/hyperactivity disorder (ADHD) is one of the most common health disorders among children. Some patients do not respond to methylphenidate or cannot tolerate its side effects. Sweet almond syrup as a Persian Medicine preparation has been used for many years. This study aims to evaluate the efficacy and safety of sweet almond for ADHD children.Fifty children aged 6 (...) -14 years with ADHD were recruited to the study. The participants were randomly assigned to two groups to receive either methylphenidate or sweet almond syrup. The outcomes were assessed using the Parent and Teacher ADHD Rating Scale every two weeks for 8 weeks.Results showed that the two treatments had similar effects on symptom reduction in ADHD children. No significant differences were observed between the two groups (F=2.3, df=1, p=0.13, F=0.57, df=1, p=0.47).Sweet almond may be an effective

2019 Complementary Therapies in Clinical Practice

14. The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan. (PubMed)

The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan. Attention-deficit hyperactivity disorder (ADHD) is associated with higher risk for fracture. Whether the medical treatment for ADHD would mitigate the risk remains unclear. In this study, we sought to investigate the effect of methylphenidate treatment on risk for fracture, as well the moderational role of treatment duration on the risk (...) of fracture, in a large national sample. Cases less than 18 years old were identified from Taiwan's National Health Insurance Research Database with a new primary diagnosis of ADHD (ICD-9:314) between 1996 and 2013. A total of 6201 cases with ADHD were included as the study cohort. The cases were divided into 3 groups according to the duration of methylphenidate treatment (0, 1-180, and more than 180 days). All groups were followed until the end of 2013 for first diagnoses of fracture (ICD-9 codes 800

Full Text available with Trip Pro

2017 PLoS ONE

15. Methylphenidate for ADHD: have Cochrane got it wrong this time?

Methylphenidate for ADHD: have Cochrane got it wrong this time? Methylphenidate for ADHD: have Cochrane got it wrong? Search National Elf Service Search National Elf Service » » » » Methylphenidate for ADHD: have Cochrane got it wrong this time? Mar 10 2016 Posted by Recently Storebø et al (2015a) published a Cochrane systematic review on the efficacy and tolerability of methylphenidate (MPH) in children and adolescents for the treatment of attention deficit hyperactivity disorder (ADHD (...) controversy as it has challenged the quality of this prior evidence-base and suggests that there is significant uncertainty about the effectiveness of methylphenidate for the treatment of ADHD. Estimates suggest that ADHD affects around 2-5% of school-aged children and young people. Methods The authors report a Cochrane systematic review and meta-analysis of randomised controlled trials (RCTs) of methylphenidate for the treatment of children and adolescents (age 18 years or younger) with ADHD. Major

2016 The Mental Elf

16. Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials

Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials Amphetamines and methylphenidate for paediatric ADHD Search National Elf Service Search National Elf Service » » » » Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials May 24 2016 Posted by Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders, with an estimated prevalence of about 5% in school-age children (Polanczyk et al, 2007 (...) ; Polanczyk et al, 2014) and 2.5% in adults. (Simon V et al, 2009). The recommended treatment of ADHD is multimodal, including pharmacological and non-pharmacological interventions. Medications for ADHD include psychostimulant (e.g., methylphenidate and amphetamine derivatives) and non-psychostimulant drugs (e.g., atomoxetine and guanfacine). Psychostimulants are the most common drugs used for ADHD worldwide. A large body of evidence from randomised controlled trials (RCTs), summarised in several meta

2016 The Mental Elf

17. Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy

Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy Punja S, Zorzela L, Hartling L, Urichuk L, Vohra S CRD summary This review concluded that long-acting (...) the core symptoms of paediatric attention deficit hyperactivity disorder (ADHD). Searching MEDLINE, Pre-MEDLINE, CINAHL, EMBASE, PsycINFO and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for studies published in English, from 1950 to August 2012. Search terms were reported. Reference lists of included studies were scanned to identify more studies. Study selection Randomised controlled trials (RCTs) that compared long-acting methylphenidate with short-acting methylphenidate

Full Text available with Trip Pro

2013 DARE.

18. Virtual Remediation Versus Methylphenidate to Improve Distractibility in Children With ADHD: A Controlled Randomized Clinical Trial Study. (PubMed)

Virtual Remediation Versus Methylphenidate to Improve Distractibility in Children With ADHD: A Controlled Randomized Clinical Trial Study. Virtual environments have been used to assess children with ADHD but have never been tested as therapeutic tools. We tested a new virtual classroom cognitive remediation program to improve symptoms in children with ADHD.In this randomized clinical trial, 51 children with ADHD (7-11 years) were assigned to a virtual cognitive remediation group (...) , a methylphenidate group, or a psychotherapy group. All children were evaluated before and after therapy with an ADHD Rating Scale, a Continuous Performance Test (CPT), and a virtual classroom task.After therapy by virtual remediation, children exhibited significantly higher numbers of correct hits on the virtual classroom and CPT. These improvements were equivalent to those observed with methylphenidate treatment.Our study demonstrates for the first time that a cognitive remediation program delivered

2018 Journal of attention disorders

19. Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study. (PubMed)

Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study. Attention deficit/hyperactivity disorder (ADHD) symptoms are common in youth with autism spectrum disorders (ASD) and are frequently treated with stimulant medications. Twenty-seven children were randomized to different dose titration schedules, and ADHD symptoms, tolerability, and aberrant behaviors were assessed weekly (...) during a 6-week trial with long-acting liquid methylphenidate (MPH). MPH at low to moderate doses was effective in reducing ADHD symptoms and was well tolerated in young children with ASD and ADHD. Future studies are needed to assess generalization and maintenance of efficacy.

2018 Journal of autism and developmental disorders

20. Sluggish Cognitive Tempo as a Possible Predictor of Methylphenidate Response in Children With ADHD: A Randomized Controlled Trial. (PubMed)

Sluggish Cognitive Tempo as a Possible Predictor of Methylphenidate Response in Children With ADHD: A Randomized Controlled Trial. To examine whether sluggish cognitive tempo (SCT) symptomatology moderates dose response to methylphenidate and whether the impact of SCT on medication response is distinct from attention-deficit/hyperactivity disorder (ADHD) subtype effects.Stimulant-naive children with ADHD predominantly inattentive type (ADHD-I; n = 126) or ADHD combined type (ADHD-C; n = 45 (...) ) aged 7-11 years were recruited from the community from September 2006 to June 2013 to participate in a prospective, randomized, double-blind, 4-week crossover trial of long-acting methylphenidate. ADHD diagnosis and subtype were established according to DSM-IV criteria using a structured interview and teacher ADHD symptom ratings. SCT symptoms were assessed using a teacher-rated scale with 2 factors (Sluggish/Sleepy and Daydreamy). Primary outcomes included (1) categorization of children

2018 Journal of Clinical Psychiatry

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>